Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lymphocyte antigen 6 complex, locus A (Ly6a), commonly known as Sca-1, is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the Ly6/uPAR family. While traditionally recognized as a marker for hematopoietic stem cells in mice, it has been identified as the critical receptor for the engineered adeno-associated virus (AAV) variant AAV-PHP.eB. This capsid variant interacts with Ly6a on the luminal surface of brain microvascular endothelial cells to facilitate highly efficient receptor-mediated transcytosis across the blood-brain barrier (BBB), enabling widespread gene delivery to the central nervous system (CNS) following systemic administration. The interaction between AAV-PHP.eB and Ly6a is highly species- and strain-specific; it is present in C57BL/6J mice but absent in BALB/c mice and primates, including humans. This lack of conservation presents a significant challenge for the clinical translation of AAV-PHP.eB-based therapies for neurodegenerative diseases. Consequently, research is ongoing to identify human orthologs, such as LY6E, that might serve as functional equivalents for CNS-targeted delivery in humans. Despite these translational hurdles, Ly6a remains a foundational target for understanding and engineering next-generation viral vectors for non-invasive brain gene therapy.
Receptor-mediated transcytosis across the blood-brain barrier
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lymphocyte antigen 6 complex, locus A (Ly6a) (Ly6a).